Abstract
Desmopressin (dDAVP), a synthetic analog of the neurohypophyseal nonapeptide arginine vasopressin, has enhanced antidiuretic potency, markedly diminished pressor activity, and a prolonged half-life and duration of action compared to the natural hormone. Desmopressin is the treatment of choice for central diabetes insipidus and can be administered either intranasally or parenterally. A newly approved indication is treatment of mild classical hemophilia and von Willebrand's disease, in which deficient concentrations of factor VIII and von Willebrand's factor are transiently increased to levels that allow minor surgery.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Anemia, Sickle Cell / drug therapy
-
Animals
-
Arginine Vasopressin* / analogs & derivatives
-
Arginine Vasopressin* / metabolism
-
Arginine Vasopressin* / pharmacology
-
Arginine Vasopressin* / therapeutic use
-
Deamino Arginine Vasopressin* / adverse effects
-
Deamino Arginine Vasopressin* / metabolism
-
Deamino Arginine Vasopressin* / pharmacology
-
Deamino Arginine Vasopressin* / therapeutic use
-
Diabetes Insipidus / drug therapy
-
Drug Synergism
-
Enuresis / drug therapy
-
Hemophilia A / drug therapy
-
Humans
-
Kidney Concentrating Ability / drug effects
-
Learning / drug effects
-
Memory Disorders / drug therapy
-
Structure-Activity Relationship
-
Urinary Incontinence / drug therapy
-
von Willebrand Diseases / drug therapy
Substances
-
Arginine Vasopressin
-
Deamino Arginine Vasopressin